Kyle Piskel
Known title: Principal Accounting OfficerCIK: 0001780662
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 3,115 | $41K | 5/18/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 18,672 | $246K | 3/11/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 61,875 | $0 | 3/4/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 2,145 | $26K | 2/4/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,145 | $40K | 2/4/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 4,290 | $52K | 1/12/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 4,290 | $77K | 1/12/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 11,980 | $78K | 11/28/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,750 | $29K | 11/28/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 94,384 | $1.1M | 11/28/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 162,820 | $3.2M | 11/28/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 238 | $3K | 11/17/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,929 | $17K | 5/16/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 7,815 | $0 | 5/15/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 2,500 | $16K | 3/14/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,103 | $22K | 3/5/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 253 | $2K | 3/5/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,964 | $49K | 3/5/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 125,000 | $0 | 3/4/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 248 | $1K | 11/18/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 31,260 | $0 | 5/15/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 7,727 | $27K | 3/5/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 43,740 | $0 | 3/4/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 259 | $1K | 11/16/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 43,735 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,300 | $28K | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 229 | $2K | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 959 | $9K | 11/16/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 220 | $3K | 3/7/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 41,186 | $0 | 3/4/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 3,837 | $0 | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.